Human vitreous distribution of linezolid after a single oral dose

Retina

Volumn 25, Issue 5, 2005, Pages 619-624

  Ciulla, Thomas A ^a   Comer, Grant M ^b   Peloquin, Charles ^c   Wheeler, Jackie ^a  

^a MIDWEST EYE INSTITUTE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; DALFOPRISTIN PLUS QUINUPRISTIN; LINEZOLID; VANCOMYCIN;

ADULT; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CLINICAL ARTICLE; DRUG DISTRIBUTION; ENDOPHTHALMITIS; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; POSTOPERATIVE INFECTION; RETINA MACULA HOLE; SINGLE DRUG DOSE; VITRECTOMY; VITREOUS BODY;

ACETAMIDES; ADMINISTRATION, ORAL; AGED; ANTI-INFECTIVE AGENTS; BIOLOGICAL AVAILABILITY; BLOOD-RETINAL BARRIER; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; OXAZOLIDINONES; RETINAL DISEASES; VITRECTOMY; VITREOUS BODY;

EID: 23044457679     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006982-200507000-00013     Document Type: Article

References (28)

1. Endophthalmitis Vitrectomy Study Group. Results of the Endophthalmitis Vitrectomy Study - a randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Arch Ophthalmol 1995;113:1479-1496.
2. el-Massry A, Meredith T, Aguilar H, et al. Aminoglycoside levels in the rabbit vitreous cavity after intravenous administration. Am J Ophthalmol 1996;122:684-689.
3. Baker A, Durand M. The Endophthalmitis Vitrectomy Study [comment]. Arch Ophthalmol 1996;114:1025-1026.
4. Han D, Wisniewski S, Wilson L, et al. Spectrum and susceptibilities of microbiologic isolates in the Endophthalmitis Vitrectomy Study [published erratum appears in Am J Ophthalmol 1996;122:920]. Am J Ophthalmol 1996;122:1-17.
5. Zyvox (linezolid). Package insert. New York, NY: Pfizer, 2000.
6. Jones R, Ballow C, Bidenbach D. Multi-laboratory assessment of the linezolid spectrum of activity using the Kirby-Bauer disk diffusion method: report of the Zyvox® antimicrobial potency study (ZAPS) in the United States. Diagn Microbiol Infect Dis 2001;40:59-66.
7. Cottagnoud P, Gerber C, Acosta F, et al. Linezolid against penicillin-sensitive and resistant pneumococci in the rabbit meningitis model. J Antimicrob Chemother 2000;46:981-985.
8. Phillips W, Tasman W. Postoperative endophthalmitis in association with diabetes mellitus. Ophthalmology 1994;101:508-518.
9. Meinkoff J, Speaker M, Marmor M, et al. A case-control study of risk factors for postoperative endophthalmitis. Ophthalmology 1991;98:1761-1768.
10. Jager G, Brinkman C, Van-Tilburg C, et al. Pseudophakic endophthalmitis. Doc Ophthalmol 1992;82:109-114.
11. Stalker D, Jungbluth G, Hopkins N, Batts D. Pharmacokinetics and tolerance of single- and multiple-dose oral and intravenous linezolid, an oxazolidinone antibiotic, in healthy volunteers. J Antimicrob Chemother 2003;51:1239-1246.
12. Lee E, Burger S, Shah J, et al. Linezolid-associated toxic optic neuropathy: a report of 2 cases. Clin Infect Dis 2003;37:1389-1391.
13. Attassi K, Hershberger E, Alam R, Zervos M. Thrombocytopenia associated with linezolid therapy. Clin Infect Dis 2002;34:695-698.
14. Ballow C, Jones R, Biedenbach D, Group NAZR. A multicenter evaluation of linezolid antimicrobial activity in North America. Diagn Microbiol Infect Dis 2002;43:75-83.
15. Bain K, Willbrodt E. Linezolid for the treatment of resistant Gram-positive cocci. Ann Pharmacother 2001;35:566-575.
16. Pryor J, Apt L, Leopold I. Intraocular penetration of vancomycin. Arch Ophthalmol 1962;67:608-611.
17. Furgiuele F. New antibiotics: their intraocular penetration. Am J Ophthalmol 1964;58:443-447.
18. Barza M, Kane A, Baum J. Oxacillin for bacterial endophthalmitis: subconjunctival, intravenous, both, or neither? Invest Ophthalmol Vis Sci 1980;19:1348-1354.
19. Axelrod J, Klein R, Bergen R, Sheikh M. Human vitreous levels of selected antistaphylococcal antibiotics. Am J Ophthalmol 1985;100:570-575.
20. Martin D, Ficker L, Aguilar H, et al. Vitreous cefazolin levels after intravenous injection: effects of inflammation, repeated antibiotic doses, and surgery. Arch Ophthalmol 1990;108:411-414.
21. Cekic O, Batman C, Yasar U, et al. Penetration of topical, oral, and combined administered ofloxacin into the subretinal fluid. Br J Ophthalmol 1999;83:1183-1185.
22. Öztürk F, Kortunay S, Kurt E, et al. Penetration of topical and oral ciprofloxacin into the aqueous and vitreous humor in inflamed eyes. Retina 1999;19:218-222.
23. Lesk M, Ammann H, Marcil G, et al. The penetration of oral ciprofloxacin into the aqueous humor, vitreous, and subretinal fluid of humans. Am J Ophthalmol 1993;115:623-628.
24. Ng E, Samiy N, Ruoff K, et al. Treatment of experimental Staphylococcus epidermidis endophthalmitis with oral trovafloxacin. Am J Ophthalmol 1998;126:278-287.
25. Mutnick A, Biedenbach D, Turnidge J, Jones R. Spectrum and potency evaluation of a new oxazolidinone, linezolid: report from the SENTRY Antimicrobial Surveillance Program, 1998-2000. Diagn Microbiol Infect Dis 2002;43:65-73.
26. Vazquez E, Mensa J, Lopez Y, et al. Penetration of linezolid into the anterior chamber (aqueous humor) of the human eye after intravenous administration. Antimicrob Agents Chemother 2004;48:670-672.
27. Invest Ophthalmol Vis Sci 2003;44:E-abstract 1,451.
28. Invest Ophthalmol Vis Sci 2003;44:E-abstract 4,424.